Skip to main content

Verve Therapeutics, Inc. (VERV)

NASDAQ: VERV · IEX Real-Time Price · USD
45.64 0.83 (1.85%)
Oct 21, 2021 11:50 AM EDT - Market open
Market Cap2.15B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out7.95M
EPS (ttm)-25.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,126
Open44.66
Previous Close44.81
Day's Range44.14 - 45.80
52-Week Range29.50 - 78.00
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About VERV

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. The current paradigm of chronic care is fragile – requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editi...

IndustryBiotechnology
IPO DateJun 17, 2021
CEOSekar Kathiresan, M.D.
Employees63
Stock ExchangeNASDAQ
Ticker SymbolVERV
Full Company Profile

Financial Performance

Financial Statements

News

Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today...

5 hours ago - GlobeNewsWire

2 Gene-Editing Stocks to Have on Your Radar Right Now

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

Other symbols:NTLA
4 days ago - The Motley Fool

Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, toda...

3 weeks ago - GlobeNewsWire

Verve Therapeutics' Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular Disease

Verve Therapeutics Inc (NASDAQ: VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101. VERVE-101 is a potential single-course gene-editing treatmen...

4 weeks ago - Benzinga

Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021

2 months ago - GlobeNewsWire

Verve Therapeutics Gets Off to a Fast Start

The dictionary describes the word “verve” as having energy, or vitality. It seems appropriate, then, that shares of biotech startup Verve Therapeutics, Inc. ( VERV , Financial) are up nearly $170% to $5...

3 months ago - GuruFocus

Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money

Find out why these stocks are climbing higher.

Other symbols:NTLAREGN
3 months ago - The Motley Fool

Verve Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pr...

4 months ago - Business Wire

Verve Therapeutics IPO Registration Document (S-1)

Verve Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

Using CRISPR to lower cholesterol levels in monkeys

A team of researchers from Verve Therapeutics and the Perelman School of Medicine at the University of Pennsylvania has developed a CRISPR gene-editing technique that lowered the levels of cholesterol i...

5 months ago - Phys.org

Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Bl...

VerveTx Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates

5 months ago - Business Wire